| Crystal structures of agonist-bound human cannabinoid receptor CB1 T Hua, K Vemuri, SP Nikas, RB Laprairie, Y Wu, L Qu, M Pu, A Korde, ... Nature 547 (7664), 468-471, 2017 | 473 | 2017 |
| Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity O Gunduz-Cinar, KP MacPherson, R Cinar, J Gamble-George, K Sugden, ... Molecular psychiatry 18 (7), 813-823, 2013 | 338 | 2013 |
| Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures T Hua, X Li, L Wu, C Iliopoulos-Tsoutsouvas, Y Wang, M Wu, L Shen, ... Cell 180 (4), 655-665. e18, 2020 | 252 | 2020 |
| Synthon-based ligand discovery in virtual libraries of over 11 billion compounds AA Sadybekov, AV Sadybekov, Y Liu, C Iliopoulos-Tsoutsouvas, ... Nature 601 (7893), 452-459, 2022 | 208 | 2022 |
| CB1 cannabinoid receptor ligands GA Thakur, SP Nikas, A Makriyannis Mini reviews in medicinal chemistry 5 (7), 631-640, 2005 | 133 | 2005 |
| Ä9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice CA Paronis, SP Nikas, VG Shukla, A Makriyannis Behavioural pharmacology 23 (8), 802-805, 2012 | 102 | 2012 |
| Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects G Godlewski, SO Alapafuja, S Bátkai, SP Nikas, R Cinar, L Offertáler, ... Chemistry & biology 17 (11), 1256-1266, 2010 | 98 | 2010 |
| Cannabinoid receptors as therapeutic targets S Pavlopoulos, GA Thakur, SP Nikas, A Makriyannis Current pharmaceutical design 12 (14), 1751-1769, 2006 | 77 | 2006 |
| Novel 1′, 1′-chain substituted hexahydrocannabinols: 9â-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist SP Nikas, SO Alapafuja, I Papanastasiou, CA Paronis, VG Shukla, ... Journal of medicinal chemistry 53 (19), 6996-7010, 2010 | 73 | 2010 |
| Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1 ¡ DP Papahatjis, SP Nikas, T Kourouli, R Chari, W Xu, RG Pertwee, ... Journal of medicinal chemistry 46 (15), 3221-3229, 2003 | 68 | 2003 |
| Novel 1′, 1′-chain substituted Ä8-tetrahydrocannabinols DP Papahatjis, SP Nikas, T Andreou, A Makriyannis Bioorganic & medicinal chemistry letters 12 (24), 3583-3586, 2002 | 68 | 2002 |
| The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the c1 ¡position of the alkyl side chain on the structural requirements for binding to … S Durdagi, A Kapou, T Kourouli, T Andreou, SP Nikas, VR Nahmias, ... Journal of medicinal chemistry 50 (12), 2875-2885, 2007 | 59 | 2007 |
| Inhibiting fatty acid amide hydrolase normalizes endotoxin‐induced enhanced gastrointestinal motility in mice M Bashashati, MA Storr, SP Nikas, JT Wood, G Godlewski, J Liu, W Ho, ... British journal of pharmacology 165 (5), 1556-1571, 2012 | 57 | 2012 |
| Structural requirements for cannabinoid receptor probes GA Thakur, SP Nikas, C Li, A Makriyannis Cannabinoids, 209-246, 2005 | 56 | 2005 |
| Sulfonyl fluoride inhibitors of fatty acid amide hydrolase SO Alapafuja, SP Nikas, IT Bharathan, VG Shukla, ML Nasr, AL Bowman, ... Journal of medicinal chemistry 55 (22), 10074-10089, 2012 | 55 | 2012 |
| C1 ¡-cycloalkyl side chain pharmacophore in tetrahydrocannabinols DP Papahatjis, VR Nahmias, SP Nikas, T Andreou, SO Alapafuja, ... Journal of medicinal chemistry 50 (17), 4048-4060, 2007 | 54 | 2007 |
| Mapping the Melatonin Receptor. 7. Subtype Selective Ligands Based on â-Substituted N-Acyl-5-methoxytryptamines and â-Substituted N-Acyl-5-methoxy-1 … A Tsotinis, M Vlachou, DP Papahatjis, T Calogeropoulou, SP Nikas, ... Journal of medicinal chemistry 49 (12), 3509-3519, 2006 | 54 | 2006 |
| A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity V Naidoo, SP Nikas, DA Karanian, J Hwang, J Zhao, JAT Wood, ... Journal of Molecular Neuroscience 43, 493-502, 2011 | 53 | 2011 |
| Fluorescent probes for G-protein-coupled receptor drug discovery C Iliopoulos-Tsoutsouvas, RN Kulkarni, A Makriyannis, SP Nikas Expert Opinion on Drug Discovery 13 (10), 933-947, 2018 | 49 | 2018 |
| Cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal AL Li, X Lin, AS Dhopeshwarkar, AC Thomaz, LM Carey, Y Liu, SP Nikas, ... Molecular pharmacology 95 (2), 155-168, 2019 | 48 | 2019 |
